One device. No Lab. Every Answer.
RadioLife replaces lab reagents with radio frequency and AI. One device scans blood, saliva, and urine — delivering results in minutes for a fraction of a penny.
Blood testing has a
chemistry problem
Every sector of digital health has seen exponential cost reduction. Diagnostics hasn't. It's still trapped in the reagent-and-labor regime that predates the internet.
$200K+ true cost per panel
Function Health charges $499 — and still loses money on every test. The reagents, equipment, and labor behind a broad panel are staggering.
Episodic, not continuous
Blood testing happens 1-2x per year. Health data should be longitudinal — tracked weekly like heart rate from a wearable.
Anchored to infrastructure
Labs require phlebotomists, analyzers ($20K-$1M each), cold chains, and regulatory overhead. Testing can't happen where people live.
65% of costs are immunoassays
The majority of diagnostic spending goes to reagent-heavy immunoassay tests. RadioLife eliminates this entire cost category.
Diagnostics is the last holdout
against Moore's Law
DNA sequencing costs dropped 99.99%. Wearables approach $0 per reading. Blood tests? Flat for 15 years.
$1B per genome to $100. Outpaced Moore's Law 3-5x.
Per heart rate reading: $0.00003. Hardware amortized over 5+ years.
CMP still $49. Trapped in reagent + labor cost regime. No exponential applies.
RF + AI inherits compute cost curves. Per-test variable cost approaches zero.
Physics instead of chemistry
CubeScan emits radio frequencies through liquid samples. Every molecule produces a unique RF fingerprint. AI classifies the signature — no reagents, no consumables, no lab.
Insert Sample
Place blood, saliva, or urine in a standard tube. 3mL volume.
RF Scanning
Device emits controlled radio frequencies that interact with macromolecules.
Signature Capture
Each target produces a unique RF fingerprint across 1,200 data points.
AI Classification
ML models analyze patterns against trained signatures. Results in minutes.
Engineered for the
point of care
CubeScan packs laboratory-grade RF spectroscopy into a device that fits on any countertop. No reagents. No consumables. Just physics.
Reagent-Free
No consumables. Ever. CubeScan uses physics — not chemistry. No cartridges, no reagents, no waste.
AI-Powered
AI-driven spectral data processing with cloud-integrated analytics. ML models trained on 8,800+ real biological samples.
Portable
At 1.5 kg with battery power, CubeScan goes where the samples are — clinics, farms, field stations, border checkpoints.
Test. Track. Understand.
A companion app that turns every scan into actionable insight. Track biomarkers over time, build health timelines, and share results with your care team.
Instant Scan Results
Point-of-care results in under 3 minutes. No appointment, no lab visit, no waiting days for results.
Growing Marker Library
New biomarkers added via software update. Each validated marker expands the platform's utility without new hardware.
Longitudinal Tracking
Weekly scans build a health timeline. Detect trends early, monitor interventions, share with your physician.
Multi-User Support
One device serves an entire household. Individual profiles with separate health timelines and sharing controls.
Data, not promises
RadioLife isn't a theoretical concept. We've processed thousands of real biological samples with published, peer-reviewed accuracy.
Human blood, saliva, urine across multiple clinical and field settings in the US and Brazil.
Validated against RT-PCR gold standard with 871 samples. Sensitivity/specificity exceeding rapid antigen tests.
Dengue, Zika, and Chikungunya detection across 7,500+ samples. Peer-reviewed publications pending.
Active Clinical Pilot — UCLA Health
Longitudinal monitoring study tracking biomarker signatures over time against standard lab panels. IRB-approved protocol.
Field Validation — Brazil
7,500+ arbovirus samples across Brazilian clinical sites. Managed by Dr. Rodrigues in partnership with FAPES and NIH-affiliated labs.
Three markets, one platform
RadioLife's platform addresses diagnostics at every scale — from individual consumers to veterinary clinics to enterprise lab networks.
At-home and DTC testing. Function Health, Everlywell, and the wellness economy.
IDEXX dominates at ~$11B market cap. Under-served by portable, affordable tools.
Quest + Labcorp + hospital labs. Ripe for disruption via decentralized, zero-reagent testing.
Hardware + software flywheel
Every scan feeds the ML engine. More data means more markers, more users, and deeper competitive moats.
Sell Device
CubeScan hardware at <$200. One-time purchase.
Unlock Markers
SaaS subscriptions for biomarker panels. New markers via OTA updates.
Collect Data
Every scan generates proprietary RF signatures. Data moat deepens.
Improve Models
More data = better accuracy = more markers = more users.
Hardware margin on CubeScan units. B2C direct and B2B channel.
Monthly/annual plans for biomarker panel access. Per-marker or bundled.
White-label platform for vet clinics, pharma, and clinical research orgs.
Momentum that compounds
RadioLife is a funded, validated, patent-protected platform with institutional backing and active deployments.
USDA NIFA Grant
Awarded for animal diagnostic applications. Validates RF sensing for cross-species biomarker detection.
UCLA Health Pilot
Active IRB-approved clinical study for longitudinal biomarker monitoring against standard lab panels.
BARDA Completed
Successfully completed Biomedical Advanced Research program. Federal validation of platform viability.
Patent Granted (2022)
Core RF diagnostic method patented. IP covers the fundamental approach of using radio frequency signatures for biological sample analysis.
Built for the path to clearance
Our strategy starts with veterinary — lower regulatory burden, faster commercial revenue, same core technology.
Research Use Only
CubeScan in active clinical studies. No regulatory filing required for RUO.
Veterinary Launch
No FDA clearance needed. Commercial revenue via vet clinics using existing validation data.
FDA Breakthrough
Submit for Breakthrough Device designation. Accelerated review pathway.
510(k) / De Novo
Full FDA clearance for human diagnostic use. Enables clinical, DTC, and enterprise channels.
Four layers of defensibility
RadioLife's advantage is the compounding effect of proprietary data, patented hardware, and a platform that gets smarter with every scan.
Signature Library
Every validated marker adds to a proprietary RF database. More markers = more defensible IP.
Data Network Effects
More devices = more scans = better models = higher accuracy. Each user makes the platform smarter.
Zero Marginal Cost
No reagents, no consumables. Competitors face per-test COGS. RadioLife's cost is compute — and compute gets cheaper.
Platform Lock-In
B2B partners co-develop markers on CubeScan. Switching costs increase as their library grows.
Built by operators and scientists
Sergio Ribeiro
Founder & CEOComputer science background. Previous telecom exit. Personally invested $350K. Designed and patented CubeScan technology.
Michelle McGuinness
Compliance AdvisorFormer Johnson & Johnson and AstraZeneca. Deep regulatory and compliance expertise in diagnostics.
Dr. Rodrigo Rodrigues
Co-Founder & CSOImmunologist, Vanderbilt-trained. 20+ years in diagnostic tests. Led clinical validation across 7,500+ arbovirus samples.
Lt. Dave Shoemaker
Regulatory AdvisorFeatured in "Bad Blood" (Ch. 10) as the expert who identified Theranos' regulatory failures.
Leonardo Vieira
Strategic Advisor — TractianCo-founder of Tractian (AI-powered industrial monitoring). Expertise in hardware-software platform scaling.
John Matthews
Technical Advisor — M/EEngineering and product development expertise. Advising on hardware manufacturing and supply chain.
Seed Round
$5M18–24 months of runway to reach Series A milestones
FDA Breakthrough Filing
Submit platform-level breakthrough designation application
Biomarker Panels
Validated signatures across metabolic, inflammatory, and pathogen markers
Pilot Deployments
Commercial revenue via giardia and coronavirus detection in companion animals
Consumer Prototype
At-home device with mobile app and initial marker library for beta